



Siemens Medical Solutions USA, Inc.
% Mr. Andrew Turner
Regulatory Affairs Specialist
40 Liberty Boulevard, Mailcode 65-1A
MALVERN PA 19355

September 8, 2020

Re: K202014

Trade/Device Name: MAGNETOM Aera, MAGNETOM Skyra, Magnetom
Prisma/Prisma^{fit} with syngo MR XA30A

Regulation Number: 21 CFR 892.1000

Regulation Name: Magnetic resonance diagnostic device

Regulatory Class: Class II

Product Code: LNH, LNI, MOS

Dated: July 17, 2020

Received: July 21, 2020

Dear Mr. Turner:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for

devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

For

Thalia T. Mills, Ph.D.
Director
Division of Radiological Health
OHT7: Office of In Vitro Diagnostics
and Radiological Health
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K202014

Device Name

MAGNETOM Aera, MAGNETOM Skyra, MAGNETOM Prisma/Prisma Fit with syngo MR XA30A

Indications for Use (Describe)

Your MAGNETOM system is indicated for use as a magnetic resonance diagnostic device (MRDD) that produces transverse, sagittal, coronal, and oblique cross sectional images, spectroscopic images and/or spectra, and that displays the internal structure and/or function of the head, body, or extremities. Other physical parameters derived from the images and/or spectra may also be produced. Depending on the region of interest, contrast agents may be used. These images and/or spectra and the physical parameters derived from the images and/or spectra, when interpreted by a trained physician, yield information that may assist in diagnosis.

Your MAGNETOM system may also be used for imaging during interventional procedures when performed with MR compatible devices such as in-room display and MR-safe biopsy needles.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the Safe Medical Devices Act 1990 and 21 CFR § 807.92.

1. General Information

Establishment: Siemens Medical Solutions USA, Inc.
40 Liberty Boulevard
Mail Code 65-1A
Malvern, PA 19355, USA
Registration Number: 2240869

Date Prepared: July 17, 2020

Manufacturer: Siemens Healthcare GmbH
Henkestrasse 127
91052 Erlangen
Germany
Registration Number: 3002808157
Siemens Shenzhen Magnetic Resonance LTD.
Siemens MRI Center
Hi-Tech Industrial park (middle)
Gaoxin C. Ave., 2nd
Shenzhen 518057, P.R. CHINA
Registration Number: 3004754211

2. Contact Information

Andrew Turner,
Regulatory Affairs Technical Specialist
Siemens Medical Solutions USA, Inc.
40 Liberty Boulevard
Mail Code 65-1A
Malvern, PA 19355, USA
Phone: (610) 850-5627
Fax: (610) 448-1787
E-mail:

3. Device Name and Classification

Device/Trade name: MAGNETOM Aera, MAGNETOM Skyra, MAGNETOM Prisma/ Prisma^{fit} with *syngo* SW XA30A

Classification Name: Magnetic Resonance Diagnostic Device (MRDD)

Classification Panel: Radiology

CFR Code: 21 CFR § 892.1000

Classification: II

Product Code: Primary: LNH
Secondary: LNI, MOS

4. Legally Marketed Predicate Device

Trade name: MAGNETOM Vida

510(k) Number: K192924

Classification Name: Magnetic Resonance Diagnostic Device (MRDD)

Classification Panel: Radiology

CFR Code: 21 CFR § 892.1000

Classification: II

Product Code: Primary: LNH
Secondary: LNI, MOS

5. Intended Use

The indications for use for the subject devices are the same as the predicate device:

Your MAGNETOM system is indicated for use as a magnetic resonance diagnostic device (MRDD) that produces transverse, sagittal, coronal and oblique cross sectional images, spectroscopic images and/or spectra, and that displays the internal structure and/or function of the head, body, or extremities. Other physical parameters derived from the images and/or spectra may also be produced. Depending on the region of interest, contrast agents may be used. These images and/or spectra and the physical parameters derived from the images and/or spectra when interpreted by a trained physician yield information that may assist in diagnosis.

Your MAGNETOM system may also be used for imaging during interventional procedures when performed with MR compatible devices such as in-room displays and MR Safe biopsy needles.

6. Device Description

MAGNETOM Aera, MAGNETOM Skyra and MAGNETOM Prisma/ Prisma^{fit} with software *syngo* MR XA30A, include new and modified hardware and software compared to the predicate device, MAGNETOM Vida with software *syngo* MR XA20A. A high-level summary of the new and modified hardware and software is provided below:

Hardware

- New Computer

Software

New Features and Applications

- **SVS_EDIT** is a special variant of the SVS_SE pulse sequence type, which acquires two different spectra (one with editing pulses on resonance, one with editing pulses off resonance) within a single sequence.
- **BEAT_FQ_nav** is a pulse sequence that allows the user to make use of navigator echo based respiratory gating for flow imaging to acquire 4D flow data. Both navigator echo based respiratory gating and flow imaging are cleared features available on the predicate device. However, the combination of the two is new.
- **Injector coupling** is a software application that allows the connection of certain contrast agent injectors to the MR system for simplified, synchronized contrast injection and examination start.
- The **Prostate Dot Engine** provides an assisted and guided workflow for prostate imaging. This automated workflow leads to higher reproducibility of slice angulation and coverage based on the segmentation algorithm described and cleared with *syngo*.via VB40; this may support exams not having to be repeated.

Modified Features and Applications

- An optimized **high bandwidth inversion recovery** pulse is combined with gradient echo readout to improve diagnostic image quality when imaging myocardial tissue.
- The **AbsoluteShim** mode is a shimming procedure based on a 3-echo gradient echo protocol.

Other Modifications and / or Minor Changes

- **Elastography-AddIn** synchronizes settings between the Elastography sequence and the active driver.
- **HASTE MoCo** is an image-based motion correction function in the average-dimension for the HASTE pulse sequence type.
- **Coil independent pulse sequences** remove the coil information from the pulse sequences and generate this information during run-time from automatic coil detection and localization.

7. Substantial Equivalence

MAGNETOM Aera, MAGNETOM Skyra and MAGNETOM Prisma/ Prisma^{fit} with software *syngo* MR XA30A are substantially equivalent to the following predicate device:

| Predicate Device | FDA Clearance Number and Date | Product Code | Manufacturer |
|--|---------------------------------|-----------------|-------------------------|
| MAGNETOM Vida with <i>syngo</i> MR XA20A | K192924, cleared March 11, 2020 | LNH LNI, MOS | Siemens Healthcare GmbH |

MAGNETOM Aera, MAGNETOM Skyra and MAGNETOM Prisma/ Prisma^{fit} with software *syngo* MR XA30A include hardware and software already cleared on the following reference devices:

| Reference Devices | FDA Clearance Number and Date | Product Code | Manufacturer |
|--|-----------------------------------|-----------------|--------------------------------------|
| MAGNETOM Aera, MAGNETOM Skyra and MAGNETOM Prisma/ Prisma ^{fit} with software <i>syngo</i> MR VE11C | K153343, cleared April 15, 2016 | LNH LNI, MOS | Siemens AG / Siemens Healthcare GmbH |
| <i>syngo.via</i> VB40 | K192462, Cleared January 31, 2020 | LLZ, LNH | Siemens Healthcare GmbH |

8. Technological Characteristics

The subject devices, MAGNETOM Aera, MAGNETOM Skyra and MAGNETOM Prisma/ Prisma^{fit} with software *syngo* MR XA30A, are substantially equivalent to the predicate device with regard to the operational environment, programming language, operating system and performance.

The subject devices conform to the standard for medical device software (IEC 62304) and other relevant IEC and NEMA standards.

As seen above there are some differences in technological characteristics between the subject devices and predicate device, including different hardware and modified software. These differences have been tested and the conclusions from the non-clinical data suggests that the features bear an equivalent safety and performance profile to that of the predicate device.

9. Nonclinical Tests

The following performance testing was conducted on the subject devices.

| Performance Test | Tested Hardware or Software | Source/Rationale for test |
|--|--|--|
| Sample clinical images | Coils, new and modified software features | Guidance for Submission of Premarket Notifications for Magnetic Resonance Diagnostic Devices |
| Image quality assessments using sample clinical images. In some cases, a comparison of the image quality / quantitative data was made. | - new / modified pulse sequence types and algorithms. - comparison images between the new / modified features and the predicate device features | |
| Performance bench test | new and modified hardware | |
| Software verification and validation | new and modified software features | Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices |

The results from each set of tests demonstrate that the devices perform as intended and are therefore, substantially equivalent to the predicate device to which it has been compared.

10. Clinical Tests / Publications

No clinical tests were conducted to support substantial equivalence for the subject devices; however, as stated above, sample clinical images were provided. Clinical publications were referenced to provide information on the use of the following features and functions.

| Feature / Function | Clinical Publication |
|---------------------|---|
| SVS_EDIT | [1] Mescher et al, Simultaneous in vivo spectral editing and water suppression, NMR Biomed 11, 266–272 (1998) |
| | [2] Mikkelsen et al, Big GABA: Edited MR spectroscopy at 24 research sites, NeuroImage 159, 32–45 (2017) |
| | [3] Saleh et al, Multi-vendor standardized sequence for edited magnetic resonance spectroscopy, NeuroImage 189, 425–431 (2019) |
| Prostate Dot Engine | [7] Essner M, Zinsser D, Kündel M, et. al. Performance of an Automated Workflow for Magnetic Resonance Imaging of the Prostate: Comparison With a Manual Workflow. Invest Radiol. 2020 May;55(5):277-284. Doi: 10.1097. |
| | [8] Horger W, Thoerner G, Weiland E, et. al. Prostate Dot Engine – a system guided and assisted workflow to improve consistency in prostate MR exams. |
| | [9] Yadong C, Siyuan H, Chunmei Li, et. al. Performance and Reproducibility of a Day Optimizing Throughput (Dot) Workflow Engine in Automated Prostate MRI Positioning. Abstract accepted for the 28th annual meeting of the International Society of Magnetic Resonance in Medicine (ISMRM). |

11. Safety and Effectiveness

The device labeling contains instructions for use and any necessary cautions and warnings to ensure safe and effective use of the device.

Risk Management is ensured via a risk analysis in compliance with ISO 14971, to identify and provide mitigation of potential hazards early in the design cycle and continuously throughout the development of the product. Siemens Healthcare GmbH adheres to recognized and established industry standards, such as the IEC 60601-1 series, to minimize electrical and mechanical hazards. Furthermore, the device is intended for healthcare professionals familiar with and responsible for the acquisition and post processing of magnetic resonance images.

MAGNETOM Aera, MAGNETOM Skyra and MAGNETOM Prisma/ Prisma^{fit} with software *syngo* MR XA30A conform to the following FDA recognized and international IEC, ISO and NEMA standards:

| Recognition Number | Product Area | Title of Standard | Reference Number and date | Standards Development Organization |
|--------------------|--------------|---|-------------------------------------|------------------------------------|
| 19-4 | General | Medical electrical equipment - part 1: general requirements for basic safety and essential performance | ES60601-1:2005/(R) 2012 and A1:2012 | AAMI / ANSI |
| 19-8 | General | Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances - Requirements and tests | 60601-1-2 Edition 4.0 2014-02 | IEC |
| 12-295 | Radiology | Medical electrical equipment - Part 2-33: Particular requirements for the basic safety and essential performance of magnetic resonance equipment for medical diagnosis | 60601-2-33 Ed. 3.2 B:2015 | IEC |
| 5-40 | General | Medical devices - Application of risk management to medical devices | 14971: 2007 | ISO |
| 5-114 | General | Medical devices – Application of usability engineering to medical devices | 62366-1:2015 | AAMI ANSI IEC |

| | | | | |
|--------|------------------|---|---------------------------|---------------------|
| 13-79 | Software | Medical device software - Software life cycle processes | 62304 Edition 1.1 2015-06 | AAMI ANSI IEC |
| 12-232 | Radiology | Acoustic Noise Measurement Procedure for Diagnosing Magnetic Resonance Imaging Devices | MS 4:2010 | NEMA |
| 12-288 | Radiology | Characterization of Phased Array Coils for Diagnostic Magnetic Resonance Images (MRI) | MS 9:2008 | NEMA |
| 12-300 | Radiology | Digital Imaging and Communications in Medicine (DICOM) Set 03/16/2012 Radiology | PS 3.1 - 3.20 (2016) | NEMA |
| 2-220 | Biocompatibility | biological evaluation of medical devices - part 1: evaluation and testing within a risk management process (Biocompatibility) | 10993-1: 2009 | AAMI ANSI ISO |

12. Conclusion as to Substantial Equivalence

MAGNETOM Aera, MAGNETOM Skyra and MAGNETOM Prisma/ Prisma^{fit} with software *syngo* MR XA30A have the same intended use and same basic technological characteristics as the predicate device system, MAGNETOM Vida with *syngo* MR XA20A, with respect to the magnetic resonance features and functionalities. While there are some differences in technical features compared to the predicate device, the differences have been tested and the conclusions from all verification and validation data suggest that the features bear an equivalent safety and performance profile to that of the predicate device and reference devices.

Siemens believes that MAGNETOM Aera, MAGNETOM Skyra and MAGNETOM Prisma/ Prisma^{fit} with software *syngo* MR XA30A are substantially equivalent to the currently marketed device MAGNETOM Vida with software *syngo* MR XA20A (K192924, cleared on March 11, 2020).